Advanced Cell Technology Financial Statements
Advanced Cell Technology Financial Information
Advanced Cell Technology Stock Quote & Chart
| 11/06/09 15:59:57 EST •
NASDAQ OTC BB •
0.10
•
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Advanced Cell Technology Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 40.98 | 7.55 | 7.01 |
| Price/Earnings Ratio | (0.63) | 93.46 | 25.51 |
| Price/Book Ratio | (0.68) | 3.48 | 6.74 |
| Price/Cash Flow Ratio | (36.90) | 41.49 | 43.48 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Advanced Cell Technology Financial Ratios
Advanced Cell Technology Competitive Intelligence
| Genzyme | Geron | StemCells | |
|---|---|---|---|
| Annual Sales ($ mil.) | 4,605.0 | 2.8 | 0.2 |
| Employees | 11,000 | 159 | 55 |
| Market Cap ($ mil.) | 13,874.2 | 502.1 | 133.7 |
Competitive Landscape



